Siamab Therapeutics' Series B - III Round

Siamab Therapeutics raised a round of funding on July 30, 2013.

Siamab Therapeutics, formerly Sialix, is a biopharmaceutical company developing novel cancer immunotherapies. Siamab has developed a platform of technologies that enable the rapid discovery and develo…

Articles about Siamab Therapeutics' Series B - III Round: